Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: The DATE (duration of dual antiplatelet therapy after implantation of endeavor stent) registry

Joo Yong Hahn, Young Bin Song, Jin Ho Choi, Sung Hyuk Choi, Sung Yun Lee, Hun Sik Park, Seung Ho Hur, Sahng Lee, Kyoo Rok Han, Seung Woon Rha, Byung Ryul Cho, Jong Sun Park, Junghan Yoon, Do Sun Lim, Sang Hoon Lee, Hyeon Cheol Gwon

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: The optimal duration of dual antiplatelet therapy remains controversial. Methods and Results: Between December 2006 and March 2008, 823 patients were enrolled in a prospective multicenter registry for 3-month dual antiplatelet therapy (aspirin 100-200 mg+clopidogrel 75 mg daily) followed by aspirin mono-therapy after zotarolimus-eluting stents (ZES). Major exclusion criteria were: cardiogenic shock, stent thrombosis (ST)-segment elevation myocardial infarction (MI) within 48 h, previous drug-eluting stent implantation, severe left ventricular dysfunction, bifurcation lesions requiring 2-stenting, left main and graft lesions. The primary outcome was a composite of cardiac death, MI, or ST at 1 year. The median duration of dual antiplatelet therapy was 95 days (interquartile range 90-101). At 1 year, 3 patients (0.4%) had cardiac deaths, 3 patients (0.4%) had MI, and 4 patients (0.5%) had definite or probable ST, leading to the primary outcome in 5 patients (0.6%). Death, MI, or any revascularization occurred in 68 patients (8.3%). Among patients who were event-free at 3 months (n=812), clopidogrel was discontinued at 3 months in 661 patients and was continued for longer than 3 months in 151 patients. Discontinuation of clopidogrel at 3 months did not increase the primary outcome (HR 0.90; 95%CI, 0.09-9.02), death, MI, or any revascularization (HR 0.89; 95%CI, 0.48-1.67) after adjustment for the propensity score. Conclusions: Three-month dual antiplatelet therapy seems to be feasible after ZES implantation in relatively low-risk patients.

Original languageEnglish
Pages (from-to)2314-2321
Number of pages8
JournalCirculation Journal
Volume74
Issue number11
DOIs
Publication statusPublished - 2010 Nov

Keywords

  • Antiplatelets
  • Drug-eluting stents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: The DATE (duration of dual antiplatelet therapy after implantation of endeavor stent) registry'. Together they form a unique fingerprint.

Cite this